Monitor for upcoming commercial rollout metrics, surgeon adoption rates, and potential partnership announcements. The appointment of a commercial-focused President suggests near-term emphasis on revenue generation, which could catalyze investor interest if early traction is demonstrated.
Price Chart
Executive Summary
SINTX Technologies announced a clinical milestone with the first human implant of its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and appointed Ryan Elmore as President to lead commercialization. These developments, along with platform expansion and manufacturing upgrades, signal a strategic shift toward commercial execution and revenue generation starting in 2026.
Key Facts
- First human implant completed using the SINAPTIC Foot & Ankle Osteotomy Wedge System in March 2026
- FDA 510(k) clearance for the system was obtained in October 2025
- Ryan Elmore appointed President on March 16, 2026, bringing 15+ years of biomaterials commercialization experience
- Company raised approximately $10 million in capital during 2025
- Transitioning to AI-assisted 3D additive manufacturing to improve scalability
- Preclinical studies initiated for silicon nitride in sutures, meshes, and wound care applications
Financial Impact
Up to $10 million in capital raised in 2025; no revenue figures disclosed
Risk Factors
- No current revenue or earnings disclosed — commercial success remains speculative
- Forward-looking statements dominate; actual adoption and manufacturing scalability are unproven
- Market cap of $10M reflects high risk; dependent on execution of commercial strategy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $2.13 $1.70 | ▼ −20.19% | ▼ −18.69% | $1.71 (−19.72%) |
Oct 1, 2026 26d ago | 8-K | $2.13 $2.11 | ▼ −0.94% | ▼ −2.24% | $1.71 (−19.72%) |
Aug 19, 2026 10w ago | EFFECT | $1.59 $1.58 | ▲ +0.63% | ▲ +0.24% | $1.71 (−7.55%) |
Jul 23, 2026 13w ago | 8-K | $1.52 $1.53 | ▲ +0.66% | ▲ +0.18% | $1.71 (+12.50%) |
Jul 2, 2026 16w ago | 8-K | $1.90 $1.70 | ▼ −10.53% | ▼ −11.46% | $1.71 (−10.00%) |
Jul 1, 2026 17w ago | EFFECT | $1.87 $1.85 | ▲ +1.07% | ▲ +1.33% | $1.71 (+8.56%) |
Jun 3, 2026 20w ago | 8-K | $2.24 $2.07 | ▲ +7.59% | ▲ +3.77% | $1.71 (+23.66%) |
May 27, 2026 21w ago | 8-K | $2.29 $2.08 | ▲ +9.17% | ▲ +10.38% | $1.71 (+25.33%) |
Mar 23, 2026 31w ago | Press Release | $2.55 $2.29 | ▼ −10.20% | ▼ −6.63% | $1.71 (−32.94%) |
Feb 23, 2026 35w ago | Insider Cluster | $2.94 $2.82 | ▼ −4.08% | ▼ −4.70% | $1.71 (−41.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers